B of A Securities has downgraded Procept Biorobotics Corp (PRCT) from Buy to Neutral as of December 7, 2025. The current share price stands at $35.70.
This decision underscores a shift towards increased caution regarding the company's outlook. The downgrade may reflect concerns about competitive pressures, market conditions, or execution risks that could affect Procept's performance.
Procept Biorobotics Corp, based in San Jose, California, is a commercial-stage surgical robotics company focused on developing transformative solutions in urology. The firm is known for the AQUABEAM Robotic System, which utilizes advanced imaging and robotics for minimally invasive urologic surgery, particularly in treating benign prostatic hyperplasia (BPH). As of November 25, 2025, the company has a market capitalization of $1.7 billion and an earnings per share (EPS) of -1.54.
Upcoming earnings reports are scheduled for April 22, 2026, and August 4, 2026, with EPS estimates of -0.34 and -0.29, respectively. The company's recent earnings performance has shown some volatility, with a Q3 2025 EPS of -0.38, surpassing estimates by 9.5%.
Analyst consensus remains predominantly positive, with 7 ratings as Strong Buy, 9 as Buy, and 3 as Hold, indicating a general belief in Procept's potential despite the recent downgrade. Analyst ratings are subject to change as new information becomes available, and they should be considered alongside other factors when making investment decisions.